Cardiac Differentiation of Adipose Tissue-Derived Stem Cells Is Driven by BMP4 and bFGF but Counteracted by 5-Azacytidine and Valproic Acid.

Adipose Tissue-Derived Stem Cells BMP4 Basic Fibroblast Growth Factor Cardiomyocyte Small Molecules

Journal

Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 14 12 2018
accepted: 14 07 2019
entrez: 22 12 2019
pubmed: 22 12 2019
medline: 22 12 2019
Statut: ppublish

Résumé

Bone morphogenetic protein 4 (BMP4) and basic fibroblast growth factor (bFGF) play important roles in embryonic heart development. Also, two epigenetic modifying molecules, 5'-azacytidine (5'-Aza) and valproic acid (VPA) induce cardiomyogenesis in the infarcted heart. In this study, we first evaluated the role of BMP4 and bFGF in cardiac trans-differentiation and then the effectiveness of 5´-Aza and VPA in reprogramming and cardiac differentiation of human adipose tissue-derived stem cells (ADSCs). In this experimental study, human ADSCs were isolated by collagenase I digestion. For cardiac differentiation, third to fifth-passaged ADSCs were treated with BMP4 alone or a combination of BMP4 and bFGF with or without 5'-Aza and VPA pre-treatment. After 21 days, the expression of cardiac-specific markers was evaluated by reverse transcription polymerase chain reaction (RT-PCR), quantitative real-time PCR, immunocytochemistry, flow cytometry and western blot analyses. BMP4 and more prominently a combination of BMP4 and bFGF induced cardiac differentiation of human ADSCs. Epigenetic modification of the ADSCs by 5'-Aza and VPA significantly upregulated the expression of OCT4A, Our findings demonstrated the inductive role of BMP4 and especially BMP4 and bFGF combination in cardiac trans-differentiation of human ADSCs. Treatment with 5'-Aza and VPA reprogrammed ADSCs toward a more pluripotent state and increased tendency of the ADSCs for mesodermal differentiation. Although pre-treatment with 5'-Aza and VPA counteracted the cardiogenic effects of BMP4 and bFGF, it may be in favor of migration, engraftment and survival of the ADSCs after transplantation.

Identifiants

pubmed: 31863652
doi: 10.22074/cellj.2020.6582
pmc: PMC6947007
doi:

Types de publication

Journal Article

Langues

eng

Pagination

273-282

Informations de copyright

Copyright© by Royan Institute. All rights reserved.

Déclaration de conflit d'intérêts

There is no conflict of interest in this study.

Références

Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
J Transl Med. 2014 Jan 07;12:8
pubmed: 24397850
Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1793-803
pubmed: 19363129
Dev Dyn. 2000 Sep;219(1):90-5
pubmed: 10974675
Cytotechnology. 2017 Dec;69(6):885-900
pubmed: 28536871
Rejuvenation Res. 2018 Aug;21(4):360-368
pubmed: 29207913
Cardiovasc Res. 2003 May 1;58(2):460-8
pubmed: 12757880
J Mol Cell Cardiol. 2012 Sep;53(3):382-91
pubmed: 22709559
Hum Mol Genet. 2014 Oct 1;23(19):5025-35
pubmed: 24858909
Stem Cells Dev. 2009 Jul-Aug;18(6):831-8
pubmed: 18847317
Methodist Debakey Cardiovasc J. 2013 Oct-Dec;9(4):187-94
pubmed: 24298308
Dev Biol. 1998 Dec 15;204(2):407-19
pubmed: 9882479
Dev Dyn. 2000 Jun;218(2):383-93
pubmed: 10842364
Cell. 2001 Sep 21;106(6):709-21
pubmed: 11572777
Korean Circ J. 2017 Mar;47(2):151-159
pubmed: 28382066
Eur Heart J. 2007 Nov;28(21):2667-77
pubmed: 17933755
Biomaterials. 2015 Nov;70:94-104
pubmed: 26302234
Mol Cell Endocrinol. 2001 May 25;177(1-2):43-54
pubmed: 11377819
Stem Cells Transl Med. 2012 Jan;1(1):70-8
pubmed: 23197643
Biotechnol Lett. 2014 Dec;36(12):2581-9
pubmed: 25216643
Eur J Cell Biol. 2008 Mar;87(3):173-84
pubmed: 18037191
Circulation. 2004 Jul 20;110(3):349-55
pubmed: 15238461
Circ Res. 2007 May 11;100(9):1249-60
pubmed: 17495232
Br Med Bull. 2017 Jan 1;121(1):135-154
pubmed: 28164211
Nat Biotechnol. 2008 Nov;26(11):1269-75
pubmed: 18849973
Cardiovasc Res. 2007 May 1;74(2):244-55
pubmed: 17187766
Front Cell Dev Biol. 2016 Oct 18;4:110
pubmed: 27803896
Nat Med. 2006 Apr;12(4):459-65
pubmed: 16582917
Iran J Basic Med Sci. 2017 Nov;20(11):1200-1206
pubmed: 29299196
Circulation. 2004 Mar 16;109(10):1292-8
pubmed: 14993122
Int J Cardiol. 2007 Aug 9;120(1):92-101
pubmed: 17156864
Birth Defects Res A Clin Mol Teratol. 2003 Mar;67(3):174-80
pubmed: 12797459
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Dev Biol. 1995 Apr;168(2):567-74
pubmed: 7729588
Int J Cardiol. 2008 Jun 23;127(1):78-87
pubmed: 17714812
Nat Biotechnol. 2005 May;23(5):607-11
pubmed: 15867910
Cell Biol Int. 2010 Mar 12;34(4):415-23
pubmed: 20067445
Circ Res. 2012 Jul 6;111(2):180-90
pubmed: 22589372
Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H233-H244
pubmed: 30412442

Auteurs

Sanaz Hasani (S)

Department of Stem Cells and Regenerative Medicine, Institute for Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Department of Biology, Faculty of Science, University of Mohaghegh Ardabili, Ardabil, Iran.

Arash Javeri (A)

Department of Stem Cells and Regenerative Medicine, Institute for Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.

Asadollah Asadi (A)

Department of Biology, Faculty of Science, University of Mohaghegh Ardabili, Ardabil, Iran.

Masoumeh Fakhr Taha (M)

Department of Stem Cells and Regenerative Medicine, Institute for Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Elrctronic Address:mftaha@nigeb.ac.ir.

Classifications MeSH